Uncategorized
Heterogeneous patient response to anti-VEGF treatment suggests close monitoring, individualized approaches
COPENHAGEN, Denmark — Many questions remain about predictors and causative factors, but interindividual variability in the response to age-related macular degeneration treatment strongly suggests that an individualized approach is prudent, according to a specialist. "We do have a high degree of heterogeneity. Patients respond on a very individual basis, even with the same disease entity. This is reflected by the huge differences in the number of treatments we have to give," Frank G. Holz, MD, said at the meeting of the European Society of Ophthalmology.